metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus ipilimumab alone
	pembrolizumab (10mg/kg) vs. ipilimumab alone	1	0.69 [0.52; 0.91], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.58 [0.47; 0.72], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
	pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone	1	0.63 [0.47; 0.84], 1 RCT, I2=0% conclusive unassessable degree of certainty	0.58 [0.46; 0.73], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
versus Standard of Care (SoC)
	nivolumab alone vs. Standard of Care (SoC)	1	0.95 [0.73; 1.24], 1 RCT, I2=0% inconclusive result	1.03 [0.76; 1.40], 1 RCT, I2=0% inconclusive result	-
	pembrolizumab (10mg/kg) vs. Standard of Care (SoC)	1	0.74 [0.57; 0.96], 1 RCT, I2=0% unassessable degree of certainty	0.50 [0.39; 0.64], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
	pembrolizumab (2mg/kg) vs. Standard of Care (SoC)	1	0.86 [0.67; 1.10], 1 RCT, I2=0% inconclusive result	0.57 [0.45; 0.73], 1 RCT, I2=0% conclusive unassessable degree of certainty	-
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1	0.76 [0.41; 1.40], 1 RCT, I2=0% inconclusive result	0.66 [0.40; 1.08], 1 RCT, I2=0% inconclusive result	-